NEW YORK (dpa-AFX) – At the end of a strong month, Wall Street is likely to suffer from moderate profit-taking on Monday. The broker IG estimated the Dow Jones Industrial over an hour before the start of trading just under half a percent lower at 29,766 points.
On Friday, given the good weekly development, it was only enough for a minimal plus in the US benchmark index, after jumping over 30,000 points for the first time on Tuesday. For November he is heading for an increase in value of a good twelve percent. The annual balance has also been consistently positive since the presentation of the corona vaccine by Biontech and Pfizer on November 9th – currently a profit of 4.3 percent is indicated.
At the beginning of the week, the focus is once again on the developers of corona vaccines. Shares in Novavax lost eight and a half percent in the face of a delay of several weeks in the crucial study for its own vaccine candidate. On Friday, the shares were celebrated by investors with a price jump of more than 20 percent.
Meanwhile, the record rally at Moderna is likely to continue after the Novavax competitor announced that it wanted to be the first company to apply for approval for a corona vaccine in the EU. The application for a conditional approval should be submitted to the European Medicines Agency Ema this Monday. Before the trading session, the stocks jumped up by almost 13 percent.
The Mainz manufacturer Biontech and its US partner Pfizer have already applied for emergency approval in the USA, but not yet in the EU. Before the start of trading in New York, their papers rose in price by around two and a half and one and a half percent respectively.
At Zoom Video, investors generously distributed advance Lorberren even before the quarterly figures that were due after the end of trading: The shares of the video conferencing specialist, who is also one of the corona profiteers in view of the increased home work, rose by around three percent.
Aside from the topic of Covid-19, a mega takeover moved the hearts of the major financial data providers in the USA: S&P Global wants to take over competitor IHS Markit in a $ 44 billion share deal. Subject to official approvals, the companies involved plan to complete the acquisition in the second half of 2021. Several US media had previously reported on the upcoming deal. While the Markit titles gained a good ten percent, those from S&P Global fell by almost half a percent./gl/jha/